Unique ID issued by UMIN | UMIN000008746 |
---|---|
Receipt number | R000010270 |
Scientific Title | Analysis of C-C chemokine receptor type 5 antagonist, as an add-on treatment for HIV-1 patients with virological response but no immunological response: a pilot study |
Date of disclosure of the study information | 2012/08/21 |
Last modified on | 2017/12/23 09:37:53 |
Analysis of C-C chemokine receptor type 5 antagonist, as an add-on treatment for HIV-1 patients with virological response but no immunological response: a pilot study
Analysis of C-C chemokine receptor type 5 antagonist, as an add-on treatment for HIV-1 patients with virological response but no immunological response
Analysis of C-C chemokine receptor type 5 antagonist, as an add-on treatment for HIV-1 patients with virological response but no immunological response: a pilot study
Analysis of C-C chemokine receptor type 5 antagonist, as an add-on treatment for HIV-1 patients with virological response but no immunological response
Japan |
HIV-1 infection
Hematology and clinical oncology | Infectious disease |
Others
NO
The aim of this study is to determine the efficacy and the safety of maraviroc, a C-C chemokine receptor type 5 (CCR5) antagonist, as an add-on treatment to optimized background anti-retroviral therapy in treatment-experienced patients.
Safety,Efficacy
Exploratory
The changes of CD4+ T cell count from baseline to 24, 48 and 96 weeks.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Maraviroc (150-300mg twice daily), as an add-on treatment to optimized background anti-retroviral therapy in treatment-experienced patients.
20 | years-old | <= |
Not applicable |
Male and Female
1. Patients with HIV-1 infection
2. Age > 20 years old
3. Patients who have received > 3 classes of anti-HIV drugs for more than 48 weeks
4. Patients who were not changed anti-retroviral therapy regimen for more than 24 weeks
5. Patients with a CD4+ T cell count < 350 cells/microL
6. Patients who were not experienced a CCR5 antagonist treatment
7. No pregnat and lactating woman
8. Completed the written informed consent
1. Patients who could be changed anti-retroviral therapy regimen during the research
2. Patients with hypersensivity to CCR5 antagonist
3. Patients with severe underlyng heart diseases
4. Patients with liver cirrhosis or liver dysfunction: AST or ALT > 3 upper limit of normality
5. Patients with renal dysfunction: eGFR<60mL/min/1.73m2
6. Patients with neutrophil< 1,000/microL, hemoglobin<10g/dL, or platelet< 100,000/microL
7. Patients with severe infectious diseases such as mycobacterium infection, deep fungal infection, cytomegalovirus infection
20
1st name | |
Middle name | |
Last name | Jun Hayashi |
Kyushu-University Hospital
Department of General internal medicine
3-1-1, Maidashi, Higashi-ku, Fukuoka, Japan
092-642-5909
hayashij@gim.med.kyushu-u.ac.jp
1st name | |
Middle name | |
Last name | Masayuki Murata |
Kyushu-University Hospital
Department of General internal medicine
3-1-1 Maidashi, Higashi-ku, Fukuoka
092-642-5909
mmurata@gim.med.kyushu-u.ac.jp
Kyushu-University Hospital
Kyushu-University Hospital
Self funding
NO
九州大学病院(福岡県)
2012 | Year | 08 | Month | 21 | Day |
Unpublished
Completed
2011 | Year | 10 | Month | 27 | Day |
2011 | Year | 10 | Month | 27 | Day |
2015 | Year | 07 | Month | 31 | Day |
2016 | Year | 02 | Month | 29 | Day |
2016 | Year | 02 | Month | 29 | Day |
2016 | Year | 03 | Month | 31 | Day |
2012 | Year | 08 | Month | 21 | Day |
2017 | Year | 12 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010270
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |